Privia Health Group (NASDAQ:PRVA) CFO Sells $432,995.28 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 17,196 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $25.18, for a total value of $432,995.28. Following the completion of the sale, the chief financial officer owned 211,462 shares in the company, valued at approximately $5,324,613.16. This represents a 7.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Mountcastle also recently made the following trade(s):

• On Monday, May 11th, David Mountcastle sold 3,385 shares of Privia Health Group stock. The shares were sold at an average price of $22.60, for a total transaction of $76,501.00.
• On Monday, May 4th, David Mountcastle sold 1,206 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total transaction of $30,150.00.
• On Friday, May 1st, David Mountcastle sold 7,179 shares of Privia Health Group stock. The stock was sold at an average price of $25.03, for a total transaction of $179,690.37.
• On Thursday, April 2nd, David Mountcastle sold 5,566 shares of Privia Health Group stock. The shares were sold at an average price of $20.85, for a total transaction of $116,051.10.

Privia Health Group Stock Performance

PRVA stock opened at $27.36 on Friday. Privia Health Group, Inc. has a one year low of $18.77 and a one year high of $27.52. The firm’s fifty day moving average is $23.38 and its 200 day moving average is $22.99. The firm has a market cap of $3.45 billion, a PE ratio of 171.01, a P/E/G ratio of 2.13 and a beta of 0.83.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.11. Privia Health Group had a net margin of 0.97% and a return on equity of 2.81%. The business had revenue of $603.85 million during the quarter, compared to the consensus estimate of $560.99 million. During the same quarter in the prior year, the firm posted $0.22 earnings per share. The company’s revenue was up 25.8% compared to the same quarter last year. Research analysts predict that Privia Health Group, Inc. will post 0.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Privia Health Group

Several institutional investors have recently bought and sold shares of the company. Bayban acquired a new position in shares of Privia Health Group during the fourth quarter valued at approximately $26,000. Hantz Financial Services Inc. boosted its stake in shares of Privia Health Group by 456.2% in the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock worth $27,000 after acquiring an additional 926 shares during the last quarter. Global Retirement Partners LLC boosted its stake in shares of Privia Health Group by 579.8% in the fourth quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock worth $38,000 after acquiring an additional 1,351 shares during the last quarter. Canada Pension Plan Investment Board increased its position in shares of Privia Health Group by 48.0% during the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock worth $85,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Privia Health Group during the fourth quarter worth approximately $93,000. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on PRVA. Barclays dropped their price objective on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Evercore set a $26.00 target price on Privia Health Group in a research report on Wednesday, April 8th. Canaccord Genuity Group decreased their target price on Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, Weiss Ratings cut shares of Privia Health Group from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Privia Health Group presently has an average rating of “Moderate Buy” and a consensus price target of $31.15.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.